Buster Mannheimer
Senior Lecturer/Senior Physician | Docent
E-mail: buster.mannheimer@ki.se
Visiting address: Karolinska Institutet/Institutionen för klinisk forskning och utb, SÖS, 11883 Stockholm
Postal address: S1 Klinisk forskning och utbildning, Södersjukhuset, S1 KI SÖS Läkarprogrammet Klinisk medicin 1, 171 77 Stockholm
About me
- My research involves the adverse effects following drug treatment. Lately,
two major aims have been to study warfarin interactions and different aspects
of drug related hyponatremia.
I was born in 1973 and educated at the University of Gothenburg taking my
doctors exam in 2002. I then performed my specialization at Södersjukhuset,
qualifying as a specialist in Internal Medicine in 2007 and as a specialist
in Endocrinology and Diabetes in 2010. Since my specialization I have
continued working at Södersjukhuset and been a consultant since 2016.
I defended my thesis at Karolinska Institutet in 2009 becoming an Associate
Professor in 2016. Since 2018 I’m part time employed as the Director of
Doctoral Education of the Department of Clinical Science and Education at
Karolinska Institutet.
Research
- In 2009 I defended my thesis ”Drug-related problems with special emphasis
on drug-drug interactions”. The thesis includes pharmacogenetic,
pharmacokinetic as well as epidemiologic aspects on mainly adverse effects
due to the treatment with psychotropic drugs. Since then I have moved towards
a mainly register based research. Several projects have included the use of
the Swedish Prescribed Drug Register (SPDR) and investigated prescription
patterns but also associations with clinical outcome.
Combining the SPDR with Auricula and Journalia, registries containing data on
individuals treated with anticoagulantia we have established a cohort of
over 100 000 patients treated with warfarin. The cohort enables a unique
epidemiologic therapeutic drug monitoring approach, efficiently targeting the
effects of any added drug with regard to changes in INR and warfarin doses.
So far, we have published data on the effects of initiating carbamazepine and
amiodarone. Four of five warfarin-treated patients in whom cotreatment with
carbamazepine was initiated experienced subtherapeutic anticoagulative effect
within 3–5 weeks. The warfarin dose was subsequently increased by 49 %. For
amiodarone, a powerful inhibitor of enzymes of importance for warfarin
metabolism, the opposite effect was evident with supratherapeutic INR and a
subsequent average 25 % compensatory dose decrease. This knowledge is
important to avoid severe bleedings or thromboembolic complications due to
changes in anticoagulation caused by interactions. Onwards we plan to
investigate the effect of several additional drugs.
Another project focuses on different aspects of hyponatremia. We recently
established a cohort of over 14 000 individuals hospitalized due to
hyponatremia. Using a case control design we studied the associations between
antidepressants and hospitalization due to hyponatremia. The results
indicated a strong association between selective serotonin reuptake
inhibitors (SSRIs) and venlafaxine, and hospitalization due to hyponatremia
exclusively related to newly initiated treatment. Consequently, in patients
with clinically significant hyponatremia with newly initiated treatment with
SSRI or venlafaxine, an alternative treatment should be considered. For
patients with ongoing antidepressant treatment, other causes should be
explored. The project has a lot of potential. One future aim is to
investigate the effects of other drugs. Another is to follow the cohort over
time which will be interesting in several ways. For example we plan to
compare the cases and controls with regard to mortality.
Articles
- Article: JAMA NETWORK OPEN. 2024;7(4):e246453
- Article: ANNALS OF EPIDEMIOLOGY. 2024;91:1-7
- Article: JAMA INTERNAL MEDICINE. 2023;183(8):832-838
- Article: JOURNAL OF THE ENDOCRINE SOCIETY. 2023;7(5):bvad047
- Article: JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION. 2023;46(3):559-565
- Article: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2023;89(2):887-897
- Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2023;79(1):71-77
- Article: JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 2022;107(6):e2388-e2393
- Article: LAKARTIDNINGEN. 2021;118:21096
- Article: CLINICAL ENDOCRINOLOGY. 2021;95(3):520-526
- Article: JOURNAL OF PSYCHOPHARMACOLOGY. 2021;35(8):928-933
- Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2021;77(7):1049-1055
- Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2021;77(5):747-755
- Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2021;77(3):409-419
- Article: JOURNAL OF PSYCHOPHARMACOLOGY. 2021;35(2):184-189
- Article: JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 2020;105(10):dgaa194-e3705
- Article: ENDOCRINE. 2020;67(3):579-586
- Article: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2020;29(1):77-83
- Article: ENDOCRINE. 2019;66(3):660-665
- Article: EUROPEAN JOURNAL OF INTERNAL MEDICINE. 2019;69:20-24
- Article: THROMBOSIS AND HAEMOSTASIS. 2019;119(10):1617-1623
- Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2019;75(10):1387-1392
- Article: EUROPEAN JOURNAL OF INTERNAL MEDICINE. 2019;60:71-77
- Article: PLOS ONE. 2019;14(8):e0220685
- Article: EUROPEAN JOURNAL OF INTERNAL MEDICINE. 2019;59:65-69
- Article: PLOS ONE. 2019;14(4):e0215356
- Article: SEIZURE-EUROPEAN JOURNAL OF EPILEPSY. 2018;59:28-33
- Article: AMERICAN JOURNAL OF MEDICINE. 2018;131(1):56-63
- Article: JOURNAL OF THROMBOSIS AND HAEMOSTASIS. 2017;15(3):446-453
- Article: JOURNAL OF THROMBOSIS AND HAEMOSTASIS. 2016;14(4):765-771
- Article: THERAPEUTIC DRUG MONITORING. 2016;38(1):127-134
- Article: LAKARTIDNINGEN. 2015;112:DF37
- Article: LAKARTIDNINGEN. 2015;112:DEDP
- Article: BMC ENDOCRINE DISORDERS. 2015;15:6
- Article: PLOS ONE. 2015;10(4):e0121984
- Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2014;70(11):1375-1383
- Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2014;70(6):695-699
- Article: PLOS ONE. 2014;9(5):e97388
- Article: JOURNAL OF CLINICAL PHARMACOLOGY. 2013;53(12):1322-1327
- Article: LAKARTIDNINGEN. 2013;110(41):1807-1808
- Article: PLOS ONE. 2013;8(8):e69545
- Article: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2012;92(2):221-227
- Article: LAKARTIDNINGEN. 2010;107(22):1459
- Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2010;66(5):465-474
- Article: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2010;69(4):411-417
- Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2008;64(12):1209-1214
- Article: THERAPEUTIC DRUG MONITORING. 2008;30(5):565-569
- Article: SCANDINAVIAN CARDIOVASCULAR JOURNAL. 2007;41(4):235-241
- Article: LAKARTIDNINGEN. 2007;104(3):132-133
- Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2006;62(12):1075-1081
- Show more
All other publications
- Corrigendum: EUROPEAN JOURNAL OF INTERNAL MEDICINE. 2021;92:142-143
- Corrigendum: EUROPEAN JOURNAL OF INTERNAL MEDICINE. 2021;92:140-141
- Corrigendum: EUROPEAN JOURNAL OF INTERNAL MEDICINE. 2021;91:107-108
- Corrigendum: AMERICAN JOURNAL OF MEDICINE. 2021;134(4):554
- Corrigendum: ENDOCRINE. 2021;71(2):531
- Corrigendum: ENDOCRINE. 2021;71(2):529-530
- Corrigendum: SEIZURE-EUROPEAN JOURNAL OF EPILEPSY. 2021;84:99-100
- Review: JOURNAL OF INTERNAL MEDICINE. 2010;268(6):540-548
- Thesis / dissertation: 2009
Employments
- Senior Lecturer/Senior Physician, Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, 2024-
Degrees and Education
- Docent, Karolinska Institutet, 2016
- Degree Of Doctor Of Philosophy, Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, 2009